Overall, these previous studies showed the safety of using IL-17 inhibitors in patients with psoriasis in the setting of COVID-19 pandemic, and further supported the positive effect of IL-17 inhibitors on alleviating the course of COVID-19. Here, IL17A is linked to psoriasis.